Research programme: immunotherapeutics - Formula Pharmaceuticals

Drug Profile

Research programme: immunotherapeutics - Formula Pharmaceuticals

Alternative Names: C.I.K.-CAR.CD23; C.I.K.-CAR.CD33

Latest Information Update: 11 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Milan Bicocca
  • Developer Formula Pharmaceutical
  • Class
  • Mechanism of Action Cytokine-induced killer cell replacements; IgE receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 03 Aug 2015 Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine enters into an exclusive licensing agreement and strategic collaboration to develop cytokine induced killer cell based CAR immunotherapies
  • 11 May 2015 Formula Pharmaceuticals in-licenses allogeneic, non-viral chimeric antigen receptor (CAR) technology platform from University of Milano-Bicocca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top